HOME >> MEDICINE >> NEWS
ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting

RICHMOND, CALIF. (Monday, May 18, 1998) --- Onyx Pharmaceuticals, Inc. (Nasdaq:ONXX) today reported results from two Phase II studies of its lead anticancer viral therapeutic, ONYX-015, in patients with tumors of the head and neck. In an ongoing Phase II study combining ONYX-015 with standard chemotherapy, the company reported that nine out of ten patients with recurrent tumors have experienced tumor regressions of greater than 50 percent to date, with two patients experiencing complete responses. In addition, the company reported that 30 percent of patients treated with ONYX-015 alone had significant tumor regressions, including two complete regressions in patients with end-stage, treatment-resistant disease.

During a poster session today at the American Society of Clinical Oncology (ASCO) meeting in Los Angeles, Onyx presented interim results from a Phase II trial combining ONYX-015 with Cisplatin and 5-FU, two standard chemotherapeutic agents used in the treatment of head and neck cancers. In addition to the two patients who had complete responses, seven patients experienced between 50 and 95 percent reductions in tumor mass. The one remaining patient has experienced a 40 percent tumor regression. To date, all of the patients continue on treatment with no evidence of disease progression. The average overall response rate with Cisplatin and 5-FU alone is about 35 percent historically in patients with recurrent disease,noted David H. Kirn, M.D., director of clinical research at Onyx.

"We have seen significant tumor regression in the patients treated to date, including some complete responses, and this is a dramatic early finding," Dr. Kirn said. "But we have only evaluated ten patients at this point. While we are encouraged by these initial results, we remain cautiously optimistic."

"Of course, because this is an ongoing study, we do not yet have information regarding durability of responses. We will be able to discuss these findings with gre
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415/ 821-2413
Kureczka/Martin Associates
18-May-1998


Page: 1 2 3

Related medicine news :

1. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
2. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
3. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
4. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
5. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
6. Pharmaceuticals and personal care products
7. Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement
8. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis
9. Beyond Pharmaceuticals: Business And Academic Leaders Forecast The Future Of "Combinatorial Chemistry"
10. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
11. Melanoma Patients Sentinel Lymph Nodes (SLNS) Play A Strong Role In Disease Prognosis, UCSF Study Reports

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/16/2018)... ... October 16, 2018 , ... With a petition (case CJ-2018-04177) filed ... McLain PLLC joins a series of lawsuits filed in states around the country against ... Massage Envy locations by Massage Envy’s massage therapists. , This lawsuit alleges that ...
(Date:10/16/2018)... ... October 16, 2018 , ... ... its mission to provide simple, easy-to-use software for biopharma companies. By pairing the ... quickly answer those crucial resourcing questions without spending millions of dollars implementing a ...
(Date:10/16/2018)... Va. (PRWEB) , ... October 16, 2018 , ... ... Oct. 23-25, 2018 – Bethesda, MD, http://www.fdanews.com/fdainspectionssummit , The 13th Annual ... last year’s Inspections Summit that it sometimes feels difficult to keep up. The ...
(Date:10/16/2018)... Maine (PRWEB) , ... October 15, 2018 , ... ... Fluids product line, VALIDATE® Body Fluids, Order Number 205bf, for easier linearity and ... assist in the documentation of linearity, calibration verification and verification of the reportable ...
(Date:10/16/2018)... ... October 16, 2018 , ... AutismOne, ... host the proceedings of the 4th Annual International HPV Vaccine Education Symposium. , ... Wednesday, May 22, 2019, through Friday, May 24, 2019, with a keynote address ...
Breaking Medicine News(10 mins):
(Date:10/16/2018)... ... October 16, 2018 , ... Association Gloves & Supplies, ... alliance with The Dentists Supply Company (TDSC). TDSC operates an online ... catalog of dental supplies through tdsc.com. This strategic alliance enhances the value proposition ...
(Date:10/16/2018)... , ... October 16, 2018 , ... Cameras and monitoring ... of the home where safety plays a key role in a family’s health and ... of “Today’s Homeowner” TV hosted a “Safe At Home” satellite media event today. ...
(Date:10/16/2018)... ... October 16, 2018 , ... The iaedp™ Foundation, ... group of healthcare treatment providers who treat the full spectrum of eating disorder ... live, two-day, 12-hour track at Symposium 2019. The courses are regularly offered ...
Breaking Medicine Technology:
Cached News: